GSK PLC 2011 SR
The report outlines GlaxoSmithKline's 2011 performance across four key themes: Health for All, Our People and Communities, Our Behaviour, and Our Planet. Significant highlights include the successful Phase III trials of the RTS,S malaria vaccine candidate and a commitment to supply 125 million doses of rotavirus vaccine to the GAVI Alliance at a 95% price reduction. The company also restructured its US sales model to decouple representative compensation from prescription volumes, emphasizing ethical conduct. Environmentally, GSK achieved a 5.3% reduction in operational greenhouse gas emissions and set a long-term goal to reach a carbon-neutral value chain by 2050.
Company: GSK PLC
Sector: Manufacturing
Country: United Kingdom
Year: 2011
Type: SR
Pages: 103
GSK PLC
The report outlines GlaxoSmithKline's 2011 performance across four key themes: Health for All, Our People and Communities, Our Behaviour, and Our Planet. Significant highlights include the successful Phase III trials of the RTS,S malaria vaccine candidate and a commitment to supply 125 million doses of rotavirus vaccine to the GAVI Alliance at a 95% price reduction. The company also restructured its US sales model to decouple representative compensation from prescription volumes, emphasizing ethical conduct. Environmentally, GSK achieved a 5.3% reduction in operational greenhouse gas emissions and set a long-term goal to reach a carbon-neutral value chain by 2050.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2011
Reporting Period
Jan 1, 2011 - Dec 31, 2011
Fiscal Year
2011
Published
Feb 3, 2012
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Net Zero Target
Employees